Cargando…

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study

INTRODUCTION: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat (VF) accumulation in Japanese individuals. Therefore, this study aimed to analyze the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirai, Kohji, Tanaka, Michitaka, Fujita, Toru, Fujii, Yuka, Shimomasuda, Masatsugu, Sakai, Soichi, Samukawa, Yoshishige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318244/ https://www.ncbi.nlm.nih.gov/pubmed/30387022 http://dx.doi.org/10.1007/s12325-018-0822-x

Ejemplares similares

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study
por: Shirai, Kohji, et al.
Publicado: (2018)

PPARγ as a sensor of lipase activity and a target for the lipase inhibitor orlistat
por: Martin, Harry, et al.
Publicado: (2013)

Selection of orlistat as a potential inhibitor for lipase from Candida species
por: Khedidja, Benarous, et al.
Publicado: (2011)

The Use of Orlistat in an Adult with Lipoprotein Lipase Deficiency: A Case Report
por: Jarrett, Zachary S., et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Direct Measurement of Lipase Inhibition by Orlistat Using a Dissolution Linked In Vitro Assay
por: Lewis, Daniel R, et al.
Publicado: (2012)

Crystal structure of pathogenic Staphylococcus aureus lipase complex with the anti-obesity drug orlistat
por: Kitadokoro, Kengo, et al.
Publicado: (2020)

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
por: Sasaki, Takashi, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Effect of orlistat alone or in combination with Garcinia cambogia on visceral adiposity index in obese patients
por: Al-kuraishy, Hayder M., et al.
Publicado: (2016)

Comparison of Efficacy of Fermented Garlic and Orlistat (Lipase Inhibitor) in Obesity Management Using an Experimental Rodent Model
por: Javed, Mavra, et al.
Publicado: (2023)

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
por: Chino, Yukihiro, et al.
Publicado: (2014)

Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups
por: Gunay, Yasemin Emur, et al.
Publicado: (2023)

Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder
por: Perera, Nimalie J., et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Obesity management: Update on orlistat
por: Drew, Belinda S, et al.
Publicado: (2007)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Anti-Lipase Potential of the Organic and Aqueous Extracts of Ten Traditional Edible and Medicinal Plants in Palestine; a Comparison Study with Orlistat
por: Jaradat, Nidal, et al.
Publicado: (2017)

Orlistat in the prevention of diabetes in the obese patient
por: Mancini, Marcio C, et al.
Publicado: (2008)

Macrocytic Anemia and Thrombocytopenia Induced by Orlistat
por: Palacios-Martinez, David, et al.
Publicado: (2013)

Acute oxalate nephropathy associated with orlistat
por: Humayun, Youshay, et al.
Publicado: (2016)

Evaluation of efficacy and safety of orlistat in obese patients
por: Jain, Suyog S., et al.
Publicado: (2011)

The Effect of Orlistat on Sterol Metabolism in Obese Patients
por: Kwon, Yu-Jin, et al.
Publicado: (2022)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

High Sensitivity of Giardia duodenalis to Tetrahydrolipstatin (Orlistat) In Vitro
por: Hahn, Juliane, et al.
Publicado: (2013)

Orlistat-Induced Gut Microbiota Modification in Obese Mice
por: Ke, Jing, et al.
Publicado: (2020)

Inhibition of CpLIP2 Lipase Hydrolytic Activity by Four Flavonols (Galangin, Kaempferol, Quercetin, Myricetin) Compared to Orlistat and Their Binding Mechanisms Studied by Quenching of Fluorescence
por: Nasri, Ruba, et al.
Publicado: (2019)

Clinical and economic considerations of antiobesity treatment: a review of orlistat
por: Zohrabian, Armineh
Publicado: (2010)

Taking Orlistat: Predicting Weight Loss over 6 Months
por: Hollywood, Amelia, et al.
Publicado: (2011)

Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase
por: Fako, Valerie E., et al.
Publicado: (2014)

An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis
por: Kose, Murat, et al.
Publicado: (2015)

The Application of Quantitative (1)H-NMR for the Determination of Orlistat in Tablets
por: Sun, Shanshan, et al.
Publicado: (2017)

The effect of orlistat and weight loss diet on plasma ghrelin and obestatin
por: Pamuk, Baris, et al.
Publicado: (2018)

Risk of colorectal cancer after initiation of orlistat: matched cohort study
por: Hong, Jin-Liern, et al.
Publicado: (2013)

Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance
por: Kim, Dae Hun, et al.
Publicado: (2018)

Comparision of Efficacy and Safety of Orlistat vs Placebo in Obese Patients in Pakistan
por: Syed, Asghar Hussain, et al.
Publicado: (2020)

Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway
por: Ye, Mujie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92s398fphef9mlnf0mft4vvouv